Zobrazeno 1 - 10
of 18
pro vyhledávání: '"R V Donskikh"'
Autor:
T Yu Semiglazova, V A Klyuge, V V Semiglazov, G M Teletaeva, P V Krivorotko, G A Dashyan, R M Paltuev, E V Tkachenko, R V Donskikh, V F Semiglazov
Publikováno v:
Современная онкология, Vol 18, Iss 2, Pp 27-33 (2016)
Since 1990-s the efficiency of treatment of patients with metastatic/advanced breast cancer (MBC) was started to evaluate not only by overall survival but also by quality of life which is characterized by physical, social, mental and emotional condit
Externí odkaz:
https://doaj.org/article/9038cd9894d74b53bb7b85786a1fe593
Autor:
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, L. F. Shaikhelislamova, L. P. Gigolaeva, V. F. Semiglazov
Publikováno v:
Успехи молекулярной онкологии, Vol 10, Iss 3, Pp 8-14 (2023)
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for
Externí odkaz:
https://doaj.org/article/c0e113ef1add4fcf8c95f52edf7214f0
Autor:
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, A. P. Sokolenko, L. F. Shaykhelislamova, T. T. Tabagua, L. P. Gigolaeva, A. V. Komyakhov, K. S. Nikolaev, K. Yu. Zernov, S. S. Ereshchenko, R. M. Paltuev, A. A. Bessonov, A. S. Artemyeva, R. S. Pesotskiy, N. S. Amirov, A. S. Emelyanov, V. V. Mortada, Ya. I. Bondarchuk, V. V. Semiglazov, T. Yu. Semiglazova, V. F. Semiglazov, A. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 1, Pp 48-55 (2023)
Background. BRCA-associated triple negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer with high sensitivity to chemotherapy, which leads to increased interest in finding new treatment options for patients
Externí odkaz:
https://doaj.org/article/f7969acdde894223bd4331d72b66866d
Autor:
V. F. Semiglazov, A. I. Tseluiko, I. A. Baldueva, T. L. Nekhaeva, A. S. Artemyeva, A. G. Kudaybergenova, S. A. Protsenko, A. V. Novik, V. V. Semiglazov, R. V. Donskikh, T. Yu. Semiglazova, R. S. Pesotskiy, V. S. Apollonova, P. V. Krivorotko, A. M. Belyaev
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 248-257 (2021)
Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials of different types of tumours. In recent years, a checkpoint inhibition therapy with monoclonal antibodies that ta
Externí odkaz:
https://doaj.org/article/e7ba8a2e3c3d43869df41d7cfecb6bbe
Autor:
V. F. Semiglazov, M. A. Dzhelialova, S. S. Yerechshenko, E. T. Munaeva, R. S. Pesotsky, A. I. Tseluyko, A. S. Emelyanov, R. V. Donskikh, P. V. Krivorotko
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 232-241 (2020)
Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual i
Externí odkaz:
https://doaj.org/article/e8fbf3f337164e4cb4068fd34c80ea60
Autor:
V. F. Semiglazov, A. I. Tseluiko, R. V. Donskikh, P. V. Krivorotko, G. A. Dashyan, V. V. Semiglazov, A. V. Komyakhov
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 12-16 (2018)
Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1
Externí odkaz:
https://doaj.org/article/48163d0e0b544275bb21442847f79d0a
Autor:
G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, R. M. Paltuev, E. E. Topuzov, T. Yu. Semiglazova, E. K. Zhil’tsova, R. V. Donskikh, T. T. Tabagua, V. S. Apollonova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 11, Iss 4, Pp 46-52 (2015)
As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poorprognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients
Externí odkaz:
https://doaj.org/article/af3e095f924344fdb4f749e144760fb4
Autor:
S. S. Yerechshenko, A. S. Emelyanov, P. V. Krivorotko, R. S. Pesotsky, R. V. Donskikh, E. T. Munaeva, M. A. Dzhelialova, V. F. Semiglazov, A. I. Tseluyko
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 232-241 (2020)
Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2793933e1b85f346cfb7eb0e90c09b3
https://www.med-sovet.pro/jour/article/view/5740
https://www.med-sovet.pro/jour/article/view/5740
Autor:
V F Semiglazov, P. Krivorotko, Gulfiya Midhatovna Teletaeva, Paltuev Rm, R V Donskikh, Tkachenko Ev, V. A. Klyuge, T Yu Semiglazova, G.A. Dashyan, Vladislav Semiglazov
Publikováno v:
Современная онкология, Vol 18, Iss 2, Pp 27-33 (2016)
Since 1990-s the efficiency of treatment of patients with metastatic/advanced breast cancer (MBC) was started to evaluate not only by overall survival but also by quality of life which is characterized by physical, social, mental and emotional condit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed0f15608368d0042a5612767e31f07
https://modernonco.orscience.ru/1815-1434/article/viewFile/27066/pdf
https://modernonco.orscience.ru/1815-1434/article/viewFile/27066/pdf
Autor:
P V, Krivorotko, S V, Kanaev, V F, Semiglazov, S N, Novikov, P I, Krzhivitsky, I I, Semenov, E A, Turkevich, E A, Busko, R V, Donskikh, Zh V, Bryantseva, E A, Piskunov, E S, Trufanova, A V, Chernaya
Publikováno v:
Voprosy onkologii. 61(3)
The study included data on 168 patients with breast cancer, surgical treatment of whom was supplemented by axillary dissection (133 patients or 79.2%) or biopsy of sentinel lymph nodes (35 patients or 20.8%). The examination included ultrasound, plan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee4a8db276d98c83030b0a3c43e62724
https://pubmed.ncbi.nlm.nih.gov/26242155
https://pubmed.ncbi.nlm.nih.gov/26242155